Wegovy (Semaglutide 2.4 mg) Constipation: Alternatives Without This Side Effect

Is there a Wegovy alternative that does not cause constipation?

Constipation is a listed common adverse reaction of Wegovy, reported by 24% of adults on 2.4 mg [1]. A review of the SURPASS type 2 diabetes trials lists constipation among tirzepatide's main adverse events [6], and a 2025 network meta-analysis of 39 studies in adults with overweight or obesity without diabetes found that both semaglutide and liraglutide were associated with an increased risk of constipation [4]. The oral Wegovy tablets carry a label statement that reaction types and frequencies were similar to the injection [1].

Tirzepatide is the only one of these drugs that has been tested against semaglutide head to head. SURMOUNT-5 randomised 751 adults with obesity and no diabetes to tirzepatide or semaglutide for 72 weeks; weight change was -20.2% versus -13.7%, and gastrointestinal events were the most common adverse events in both groups [2]. Its abstract does not break out constipation by group.

How common is constipation on Wegovy?

In the Wegovy label's three pooled placebo-controlled trials, 2,116 adults received semaglutide 2.4 mg weekly and 1,261 received placebo for up to 68 weeks; constipation was reported by 24% versus 11%, and any gastrointestinal reaction by 73% versus 47% [1]. Diarrhea was more common than constipation, at 30% versus 16% [1].

The three adverse reactions most often leading to discontinuation were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%) and diarrhea (0.7% versus 0.1%), not constipation [1]. Overall, 6.8% of people on Wegovy and 3.2% on placebo stopped treatment because of an adverse reaction [1].

Raising the dose did not lower the rate. In two 72-week trials of the 7.2 mg dose, constipation was reported by 20% on 7.2 mg, 19% on 2.4 mg and 8% on placebo (1,311, 304 and 303 patients respectively) [1].

What is known about semaglutide and digestion?

Semaglutide is a GLP-1 receptor agonist that binds receptors in brain areas that regulate appetite and calorie intake, and it delays gastric emptying [1]. The label states that this delay may affect the absorption of other oral medicines and advises closer monitoring for drugs with a narrow therapeutic index [1].

Constipation sits alongside other gut effects in the label's tables: nausea 44% versus 16%, diarrhea 30% versus 16%, vomiting 24% versus 6%, abdominal pain 20% versus 10% and dyspepsia 9% versus 3% on Wegovy 2.4 mg against placebo [1].

How do the other weight-loss drugs compare?

Tirzepatide

In SURMOUNT-1, 2,539 adults with obesity or overweight without diabetes received tirzepatide 5, 10 or 15 mg or placebo for 72 weeks; mean weight change at 15 mg was -20.9% versus -3.1% on placebo, and the most common adverse events were gastrointestinal, mostly mild to moderate and occurring mainly during dose escalation [3]. A review of the SURPASS type 2 diabetes trials describes nausea, vomiting, diarrhea and constipation as tirzepatide's main adverse events [6].

In SURMOUNT-5, the head-to-head trial against semaglutide, gastrointestinal events were the most common adverse events in both arms [2].

Liraglutide 3.0 mg

In the SCALE trial, 3,731 adults without diabetes received liraglutide 3.0 mg daily or placebo for 56 weeks; weight change was -8.4 kg versus -2.8 kg, and the most frequently reported adverse events were mild or moderate nausea and diarrhea [7]. Liraglutide was also among the drugs associated with increased constipation risk in the network meta-analysis of non-diabetic adults with overweight or obesity [4].

Oral semaglutide

Rybelsus was studied in adults with type 2 diabetes [8]. Wegovy tablets are the oral semaglutide product indicated for weight management in adults, and the label says reaction types and frequencies were similar to the injection [1]. In the 71-week oral semaglutide 25 mg obesity trial, 307 adults were randomised and gastrointestinal adverse events occurred in 74.0% versus 42.2% on placebo, with mean weight change of -13.6% versus -2.2% [9].

Non-GLP-1 options

Switching drug class does not remove constipation either. A 2024 review of obesity medications notes that the centrally acting drugs phentermine-topiramate and naltrexone-bupropion are associated with constipation in approximately 20% of patients [5]. Orlistat has different gastrointestinal side effects: oily fecal spotting and urgency occur in more than 25% of patients [5].

What does the Wegovy label say about serious constipation?

Postmarketing reports in the Wegovy and Ozempic labels include ileus, intestinal obstruction and severe constipation including fecal impaction; frequency cannot be estimated from voluntary reports [1]. Severe gastrointestinal adverse reactions occurred in 4.1% of adults on Wegovy injection versus 0.9% on placebo, and the label says Wegovy is not recommended in patients with severe gastroparesis [1].